Nursing and Health Professions
Patient
100%
Continuous Infusion
50%
Toxicity
33%
Dose
33%
Liver Dysfunction
16%
Nausea and Vomiting
16%
Infusion
16%
Diarrhea
16%
Recommended Drug Dose
16%
Aspartate Aminotransferase Blood Level
16%
Antiemetic Agent
16%
Maximum Tolerated Dose
16%
Thrombocytopenia
16%
Advanced Cancer
16%
Phlebitis
16%
Intercalating Agent
16%
Medicine and Dentistry
Continuous Infusion
50%
Phase I Trials
50%
Toxicity
33%
Infusion
16%
Recommended Drug Dose
16%
Diarrhea
16%
Nausea and Vomiting
16%
Thrombocytopenia
16%
Superficial Vein
16%
Liver Dysfunction
16%
Antiemetic
16%
Advanced Cancer
16%
Phlebitis
16%
Intercalating Agent
16%
Pharmacology, Toxicology and Pharmaceutical Science
Echinomycin
66%
Phase II Trials
50%
Toxicity
33%
Diarrhea
16%
Nausea and Vomiting
16%
Liver Dysfunction
16%
Thrombocytopenia
16%
Antiemetic Agent
16%
Advanced Cancer
16%
Intercalating Agent
16%
Phlebitis
16%
Chemistry
Dose
66%
Toxicity
33%
Biochemical
16%
Antiemetic
16%